RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Clinical trials for RECURRENT SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT SMALL LYMPHOCYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-phase trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:33 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. The approach uses low-dose chemo and radiation before a donor stem cell infusion, followed by drugs to prevent graft-versus-host disease. The goal was to control the cancer…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 26, 2026 08:30 UTC
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, MOR00208 and lenalidomide, in 41 people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal was to see if the combination could shrink or control the cancer in patients who had not responded to prior treatments …
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC